Opendata, web and dolomites

GONDOLA SIGNED

Automated Mechanical Peripheral Stimulation for motor rehabilitation in people living with Parkinson’s Disease (PD)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GONDOLA project word cloud

Explore the words cloud of the GONDOLA project. It provides you a very rough idea of what is the project "GONDOLA" about.

medications    more    living    nih    body    ninds    therapies    gait    falls    motor    costly    brain    10m    neurodegenerative    families    basic    functioning    aligned    movements    peripheral    fluidity    inability    named    mechanical    inputs    mechanism    invasive    treatment    confidence    made    device    disease    central    cord    person    amps    benefits    life    reducing    hesitation    spending    7b    recommendations    induce    neurostimulations    freezing    automated    disorder    burden    advancing    portable    nervous    strategy    medical    2004    feet    treating    substantial    independence    cure    ideal    disabled    pd    regard    slowness    regulate    priorities    balance    points    neurotransmitter    regulates    afferent    dopamine    characterised    people    documented    spinal    clinical    effectiveness    pattern    undermine    stages    skills    self    generator    risk    physical    2040    neurostimulation    individuals    economic    delivers    symptoms    walking    parkinson    motions    safety    globally    ourselves    prevalence    time    lessening    gondolatm    stimulation    annual    causing    double    society    patients    efficacy    quality   

Project "GONDOLA" data sheet

The following table provides information about the project.

Coordinator
GONDOLA MEDICAL TECHNOLOGIES SA 

Organization address
address: CORSO ELVEZIA 9 A
city: LUGANO
postcode: 6900
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.gondola-parkinson.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GONDOLA MEDICAL TECHNOLOGIES SA CH (LUGANO) coordinator 50˙000.00

Map

 Project objective

Parkinson’s disease (PD) is a neurodegenerative brain disorder, characterised by the inability of a person’s brain to produce a neurotransmitter called dopamine, lessening a person’s ability to regulate body motions. PD affects 10m people globally, its prevalence is expected to double by 2040. There is no cure for PD, current therapies focus on treating symptoms that undermine patients’ quality of life. Costs associated with PD are higher than its prevalence, causing substantial economic burden on individuals, families and society. In 2004, the annual spending in Europe on PD was €10.7b. As costly as they are, these therapies improve motor symptoms in the early stages of PD, but over time, patients have more and more reduced response to medications and become more disabled. Thus, they cannot be considered as ideal with regard to efficacy, long-term effectiveness and safety. NINDS (part of the US NIH) set recommendations addressing Gait as one of the 3 top priorities for advancing basic clinical research on PD. We have aligned ourselves with NINDS’ strategy through development of GondolaTM. GondolaTM is a portable medical device made for people living with PD. It delivers a non-invasive neurostimulation treatment named Automated Mechanical Peripheral Stimulation (AMPS). It is based on physical neurostimulations of specific points in both feet, which allow to increase the afferent inputs from the peripheral nervous system to the spinal cord, and induce a better functioning of the central pattern generator (the mechanism that regulates movements in the body). Four clinical studies have documented that AMPS is effective in improving motor skills in PD, particularly slowness of movements and freezing of gait. Users have derived the following benefits from the device: Reduced Freezing of gait, gait hesitation, slowness of movements, improved independence, self-confidence, fluidity in walking and balance, reducing the risk of falls and improving the quality of life.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GONDOLA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GONDOLA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More